肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2021 SFRO建议：放射治疗在膀胱癌管理中的作用

2021-12-23 法国放射肿瘤学学会 Cancer Radiother

膀胱癌放射治疗泌尿生殖系肿瘤

2021年12月，法国放射肿瘤学学会(SFRO)发布了放射治疗在膀胱癌管理中的建议，文章主要针对膀胱癌的外照射治疗的适应证和技术提供指导建议。

中文标题：

2021 SFRO建议：放射治疗在膀胱癌管理中的作用

英文标题：

Role of radiotherapy in the management of bladder cancer: Recommendations of the French society for radiation oncology

发布机构：

法国放射肿瘤学学会

发布日期：

2021-12-23

简要介绍：

2021年12月，法国放射肿瘤学学会(SFRO)发布了放射治疗在膀胱癌管理中的建议，文章主要针对膀胱癌的外照射治疗的适应证和技术提供指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 SFRO建议：放射治疗在膀胱癌管理中的作用.pdf)] GetToolGuiderByIdResponse(projectId=1, id=5cfdf1c002313026, title=2021 SFRO建议：放射治疗在膀胱癌管理中的作用, enTitle=Role of radiotherapy in the management of bladder cancer: Recommendations of the French society for radiation oncology, guiderFrom=Cancer Radiother, authorId=0, author=, summary=2021年12月，法国放射肿瘤学学会(SFRO)发布了放射治疗在膀胱癌管理中的建议，文章主要针对膀胱癌的外照射治疗的适应证和技术提供指导建议。, cover=https://img.medsci.cn/202216/1641438043600_1608702.png, journalId=0, articlesId=null, associationId=2275, associationName=法国放射肿瘤学学会, associationIntro=法国放射肿瘤学学会(SFRO,French society for radiation oncology), copyright=0, guiderPublishedTime=Thu Dec 23 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年12月，法国放射肿瘤学学会(SFRO)发布了放射治疗在膀胱癌管理中的建议，文章主要针对膀胱癌的外照射治疗的适应证和技术提供指导建议。</span></p>, tagList=[TagDto(tagId=758, tagName=膀胱癌), TagDto(tagId=6811, tagName=放射治疗), TagDto(tagId=117298, tagName=泌尿生殖系肿瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=40, categoryName=影像放射, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=758, guiderKeyword=膀胱癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4183, appHits=37, showAppHits=0, pcHits=179, showPcHits=4146, likes=1, shares=10, comments=6, approvalStatus=1, publishedTime=Thu Jan 06 10:58:35 CST 2022, publishedTimeString=2021-12-23, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Thu Jan 06 11:02:58 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Fri Jan 05 05:20:23 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 SFRO建议：放射治疗在膀胱癌管理中的作用.pdf)])
2021 SFRO建议：放射治疗在膀胱癌管理中的作用.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1183411, encodeId=7a6d1183411e4, content=早日学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30463817971, createdName=张俊波, createdTime=Wed Jan 12 07:01:02 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183253, encodeId=3d9e1183253fc, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220212/d050090c43414f9084d330a1d2d0dafe/27e667c6f49941d2b7c02878f939fca2.jpg, createdBy=4cd06423764, createdName=ms9000001688846143, createdTime=Tue Jan 11 16:18:16 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182087, encodeId=2657118208e6e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 08 07:25:54 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181694, encodeId=72121181694a2, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Jan 07 07:31:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181343, encodeId=e9a311813437d, content=好好学习，天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e495565045, createdName=王江军, createdTime=Thu Jan 06 13:15:55 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2022-01-12 张俊波

    早日学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1183411, encodeId=7a6d1183411e4, content=早日学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30463817971, createdName=张俊波, createdTime=Wed Jan 12 07:01:02 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183253, encodeId=3d9e1183253fc, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220212/d050090c43414f9084d330a1d2d0dafe/27e667c6f49941d2b7c02878f939fca2.jpg, createdBy=4cd06423764, createdName=ms9000001688846143, createdTime=Tue Jan 11 16:18:16 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182087, encodeId=2657118208e6e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 08 07:25:54 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181694, encodeId=72121181694a2, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Jan 07 07:31:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181343, encodeId=e9a311813437d, content=好好学习，天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e495565045, createdName=王江军, createdTime=Thu Jan 06 13:15:55 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2022-01-11 ms9000001688846143

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1183411, encodeId=7a6d1183411e4, content=早日学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30463817971, createdName=张俊波, createdTime=Wed Jan 12 07:01:02 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183253, encodeId=3d9e1183253fc, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220212/d050090c43414f9084d330a1d2d0dafe/27e667c6f49941d2b7c02878f939fca2.jpg, createdBy=4cd06423764, createdName=ms9000001688846143, createdTime=Tue Jan 11 16:18:16 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182087, encodeId=2657118208e6e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 08 07:25:54 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181694, encodeId=72121181694a2, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Jan 07 07:31:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181343, encodeId=e9a311813437d, content=好好学习，天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e495565045, createdName=王江军, createdTime=Thu Jan 06 13:15:55 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2022-01-08 微探

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1183411, encodeId=7a6d1183411e4, content=早日学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30463817971, createdName=张俊波, createdTime=Wed Jan 12 07:01:02 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183253, encodeId=3d9e1183253fc, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220212/d050090c43414f9084d330a1d2d0dafe/27e667c6f49941d2b7c02878f939fca2.jpg, createdBy=4cd06423764, createdName=ms9000001688846143, createdTime=Tue Jan 11 16:18:16 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182087, encodeId=2657118208e6e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 08 07:25:54 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181694, encodeId=72121181694a2, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Jan 07 07:31:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181343, encodeId=e9a311813437d, content=好好学习，天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e495565045, createdName=王江军, createdTime=Thu Jan 06 13:15:55 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2022-01-07 微探

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1183411, encodeId=7a6d1183411e4, content=早日学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30463817971, createdName=张俊波, createdTime=Wed Jan 12 07:01:02 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183253, encodeId=3d9e1183253fc, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220212/d050090c43414f9084d330a1d2d0dafe/27e667c6f49941d2b7c02878f939fca2.jpg, createdBy=4cd06423764, createdName=ms9000001688846143, createdTime=Tue Jan 11 16:18:16 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182087, encodeId=2657118208e6e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 08 07:25:54 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181694, encodeId=72121181694a2, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Jan 07 07:31:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181343, encodeId=e9a311813437d, content=好好学习，天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e495565045, createdName=王江军, createdTime=Thu Jan 06 13:15:55 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2022-01-06 王江军

    好好学习，天天向上

    0

相关指南

2021 ESMO临床实践指南：膀胱癌的诊断，治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2021-11-27

2021 ACR适宜性标准：膀胱癌治疗后监测（更新版）

美国放射学会(ACR,American College of Radiology) · 2021-05-18

窄带成像在非肌层浸润性膀胱癌诊治中的应用安全共识（2020版）

中国医促会泌尿健康促进分会 · 2021-03-25

2020 JUA临床指实践指南：膀胱癌

日本泌尿外科协会(JUA,Japanese Urological Association) · 2020-06-21

2020 EAU指南：肌层浸润和转移性膀胱癌

欧洲泌尿外科学会(EAU,European Association of Urology) · 2020-04-29

2020 SIGO意见书：老年膀胱癌的管理

国外肿瘤科相关专家小组（统称） · 2020-02-10

拓展阅读

2014 WHO/ICUD共识：膀胱癌筛查，早期诊断和检测的分子标志物

世界卫生组织(WHO,The World Health Organization) · 2014-12-10

2015 关于膀胱癌应用膀胱内BCG免疫治疗专家共识

国外肿瘤科相关专家小组（统称） · 2015-03-24

2016AUA：非肌层浸润性膀胱癌治疗指南

美国泌尿外科学会(AUA,American Urological Association) · 2016-04-14

2016 EAU指南：肌层浸润和转移性膀胱癌（更新版）

欧洲泌尿外科学会(EAU,European Association of Urology) · 2016-06-30

2015 JUA指南：膀胱癌指南的核心内容（更新）  

日本泌尿外科协会(JUA,Japanese Urological Association) · 2016-07-03

2017 AUA/ASCO/ASTRO/SUO指南：非转移性肌浸润性膀胱癌的治疗

美国泌尿外科学会(AUA,American Urological Association) · 2017-04-26